This study is being done to learn more about Lipoprotein(a) (Lp(a) values in people with known history of Atherosclerotic Cardiovascular Disease (ASCVD). Lipoprotein(a) is a particle that carries cholesterol in the blood. ASCVD is a type of thickening or hardening of the arteries caused by a build up of plaque in the walls of arteries. Plaque is made up of substances such as fats and cholesterol. Plaque can cause blockages in the arteries which could result in a heart attack. High levels of Lp(a) are directly associated with a higher risk of cardiovascular events such as heart attacks or aortic stenosis.
Participation in this study will last up to 2 weeks and involve data collection and a blood draw for a Lipoprotein(a) level unless you've had a level checked in the past. You will be informed of your Lipoprotein(a) level.
If you are an adult over 40 years of age with atherosclerosis cardiovascular disease (heart attack or ischemic stroke or narrowing of arteries in legs due to plaque) and a LDL cholesterol greater than 70 mg/dL, you may be eligible to take part in a clinical research study. The purpose of this study is to evaluate the benefit of inclisiran on major cardiovascular events while taking either atorvastatin or rosuvastatin cholesterol lowering medications. Study participants will be randomly assigned to take either inclisiran or placebo (inactive medication). Study visits during the treatment period will occur every three months twice and then every six months for up to six years. If eligible, study medication and study visits will be provided free of charge. Compensation is available.